

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims

1. **(Currently Amended)** A composition comprising an antibody, or antigen binding fragment thereof, formulated with DTPA and DEF, wherein the concentration of DTPA is from about 0.02 mM to 1mM and the concentration of DEF is from about 0.02 mM to 0.5 mM.
2. **(Canceled)**
3. **(Original)** The composition of claim 1, further comprising EGTA.
- 4-8. **(Canceled)**
9. **(Original)** The composition of claim 1, further comprising an agent that inhibits protein aggregation.
10. **(Original)** The composition of claim 9, wherein the agent that inhibits protein aggregation is selected from the group consisting of polysorbate 80, polysorbate 20, glycerol, and a poloxamer polymer.
11. **(Original)** The composition of claim 10, wherein the agent that inhibits protein aggregation is polysorbate 80 or polysorbate 20 at a concentration of from about 0.001% to about 0.1%.
12. **(Original)** The composition of claim 1, further comprising a buffer that maintains the pH of the composition from about 5.0 to about 8.0.
13. **(Original)** The composition of claim 12, wherein the buffer is selected from the group consisting of phosphate, citrate, Tris, acetate, MES, succinic acid, PIPES, Bis-Tris, MOPS, ACES, BES, TES, HEPES, EPPS, ethylenediamine, phosphoric acid, and maleic acid.

14. **(Canceled)**
15. **(Previously Presented)** The composition of claim 1, wherein the concentration of the antibody is from about 1 μ g/mL to about 500 mg/mL.
16. **(Canceled)**
17. **(Previously Presented)** The composition of claim 1, wherein the antibody is a monoclonal antibody, or antigen binding fragment thereof.
18. **(Previously Presented)** The composition of claim 1, wherein the antibody is a human antibody, or antigen binding fragment thereof.
19. **(Previously Presented)** The composition of claim 1, wherein the antibody or fragment thereof is conjugated to an agent, selected from the group consisting of a toxin, a polymer, an imaging agent and a drug.
20. **(Previously Presented)** The composition of claim 1, wherein the antibody or fragment thereof is microencapsulated.
21. **(Original)** The composition of claim 1, wherein the composition is a pharmaceutical composition.
22. **(Canceled)**
23. **(Currently Amended)** A method for preparing a stabilized protein composition, comprising formulating an antibody, or antigen binding fragment thereof, together with DTPA and DEF in an amount effective to protect the antibody, or antigen binding fragment thereof, against oxidation, wherein the concentration of DTPA is from about 0.02 mM to 1mM and the concentration of DEF is from about 0.02 mM to 0.5 mM.
24. **(Canceled)**
25. **(Original)** The method of claim 23, wherein the composition further comprises EGTA.

26. **(Currently Amended)** The method of claim 25, wherein the concentration of DTPA or EGTA is from about 1 μ M to about 10 mM.

27-28. **(Canceled)**

29. **(Original)** The method of claim 23, further comprising adding an agent that inhibits protein aggregation to the composition.

30. **(Original)** The method of claim 23, further comprising adding a buffer that maintains the pH from about 5.0 to about 8.0 to the composition.

31. **(Original)** The method of claim 30, wherein the buffer is selected from the group consisting of about 5 mM to about 100 mM phosphate, citrate, Tris, acetate, MES, succinic acid, PIPES, Bis-Tris, MOPS, ACES, BES, TES, HEPES, EPPS, ethylenediamine, phosphoric acid, and maleic acid.

32. **(Canceled)**

33. **(Previously Presented)** The method of claim 23, wherein the concentration of the antibody or fragment thereof is from about 1 μ g/mL to about 500 mg/mL.

34. **(Canceled)**

35. **(Previously Presented)** The method of claim 23, wherein the antibody is a human antibody, or antigen binding fragment thereof.

36. **(Previously Presented)** The method of claim 23, wherein the antibody is a monoclonal antibody, or antigen binding fragment thereof.

37. **(Previously Presented)** The method of claim 23, wherein the antibody or fragment thereof is conjugated to an agent selected from a toxin, a polymer, an imaging agent or a drug.

38. **(Previously Presented)** The method of claim 23, wherein the antibody or fragment thereof is microencapsulated.

39. **(Original)** The method of claim 23, wherein the composition is a pharmaceutical composition.

40. **(Canceled)**